Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1461P - Predictive value of residual FDG-PET metabolic activity in metastatic non-small cell lung cancer (mNSCLC) patients (pts) with long-lasting response to immune checkpoint inhibitors (ICIs)

Date

21 Oct 2023

Session

Poster session 20

Topics

Nuclear Medicine and Clinical Molecular Imaging;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Toublanc Anne-Claire

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

T. Anne-Claire1, A. Crombe2, R. Veillon3, C. Domblides4, M. Cabart5, F. Chomy6, M. Zysman3, S. Cousin1

Author affiliations

  • 1 Medical Oncology, Institut Bergonié, 33076 - Bordeaux/FR
  • 2 Radiology Department, Bordeaux University Hospital, 33000 - Bordeaux/FR
  • 3 Onco-pneumology, Hopital De Haut Leveque, 33604 - Pessac/FR
  • 4 Medical Oncology Department, CHU Bordeaux - Hopital St. André, 33000 - Bordeaux/FR
  • 5 Oncologie Médicale, Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), 33000 - Bordeaux/FR
  • 6 Gironde, Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), 33000 - Bordeaux/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1461P

Background

The optimal duration of ICIs treatment in mNSCLC is debated, arbitrarily fixed to 2 years in the 1st line setting. Unfortunately, pts will mostly relapse months or years after the end of the treatment (EOT). Physicians tend to confirm the partial or complete obtained response before stopping it, by performing 18F-FDG -PET (PET). However, the interpretation of residual fixative areas remains unclear.

Methods

This is a bi-center retrospective study of mNCSLC pts who completed 2 years of ICI, or stopped it due to adverse event without progression and underwent a PET at the EOT. Collected data were: age, smoking status, PDL1 and KRAS status, type and line of treatment, ICI duration.

Results

We enrolled 80 pts who began ICIs between Sept. 2016 and Nov. 2021. Median follow up was 35.9 months. Median age was 61 years (range: 56-69), sex ratio was 1:1, 93.5% were current/former smokers, 87.5% had adenocarcinoma, 54% had PDL1>50%. ICI was given as monotherapy and as first line in 41% and 67.5% of pts respectively. Molecular analysis revealed KRAS G12C mutation in 29% pts. Median ICIs duration was 23.4 months (range: 3-48), 55 pts completed 2 years of ICI, 22 discontinued due to toxicity, 3 for others reasons. The 2-year progression-free survival (PFS) probability was 96% (range:92-100). Median SUVmax was 1.9 (range: 0-17). 55% pts had PET residual fixation (RF): 36% on initial lung tumor, 15% on mediastinal lymph nodes and 5% on extrathoracic sites. 6 pts underwent an excision surgery or a biopsy of a RF: 4 were immune-mediated inflammatory reactions, 2 found the initial histology. 6 pts were locally treated for RF by radiotherapy or surgery. Of the 17 pts who relapsed: 12 had a RF on the PET after ICIs. Conversely, 5/36 pts (14%) without RF relapsed. The presence of a RF was not associated with the PFS in univariable analysis (HR=2.4, 95%CI: 0.8-6.9, P=.121) and after adjusting for duration and type of ICI treatment (HR=1.4, 95%CI: 0.5-4.3, P=.539).

Conclusions

Positive 18F-FDG-PET/CT is not associated with relapse after completion of ICI treatment but has good negative predictive value. Treatment of oligopersistence after partial response to ICI based on PET-scan remains controversial.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Sophie Cousin.

Funding

Has not received any funding.

Disclosure

C. Domblides: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD; Financial Interests, Personal, Other, travel expenses: AstraZeneca, BMS, MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.